HYUNDAI BIOSCIENCE CO., LTD.: debt-to-equity, ROE and more
KOSDAQ, Legal name HYUNDAI BIOSCIENCE CO., LTD.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 18.1%
- Equity ratio
- 84.7%
- ROE
- -20.0%
- Op. margin
- -516.3%
- Rev. growth
- -76.6%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 1 straight year.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 30.8% | 76.5% | -32.6% | -105.7% | n/a |
| FY2022 consolidated | 15.6% | 86.5% | -27.1% | -335.7% | -15.0% |
| FY2023 consolidated | 16.6% | 85.8% | -32.0% | -103.2% | 20.8% |
| FY2024 consolidated | 71.7% | 58.3% | -17.6% | 5.3% | 58.7% |
| FY2025 consolidated | 18.1% | 84.7% | -20.0% | -516.3% | -76.6% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩9.2B | ₩7.9B | ₩9.5B | ₩15.1B | ₩3.5B |
| Operating profit | -₩9.8B | -₩26.4B | -₩9.8B | ₩791.0M | -₩18.2B |
| Pre-tax income | -₩19.8B | -₩16.6B | -₩14.5B | -₩6.9B | -₩22.1B |
| Net income | -₩20.1B | -₩15.8B | -₩14.5B | -₩6.9B | -₩22.1B |
| Total assets | ₩80.5B | ₩67.3B | ₩52.8B | ₩67.7B | ₩130.7B |
| Total liabilities | ₩19.0B | ₩9.1B | ₩7.5B | ₩28.3B | ₩20.0B |
| Total equity | ₩61.6B | ₩58.2B | ₩45.3B | ₩39.4B | ₩110.7B |
| Paid-in capital | ₩19.3B | ₩19.8B | ₩19.9B | ₩19.9B | ₩48.0B |
| Debt/equity (source value) | 30.8% | 15.6% | 16.6% | 71.7% | 18.1% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2000-05-25
- Listed
- 02/08/08
- Employees
- 67
- Auditor
- 삼정회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1344110015693
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 현대바이오Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.